[Controlled release metoprolol succinate in MERIT-HF. Analysis of patients subgroups].
Results of the investigation of metoprolol CR/XL which was conducted in large randomized controlled study MERIT-HF in patients with chronic heart failure (CHF) are presented. In the whole trial this beta1-selective blocker lowered mortality of patients with CHF. Analysis of results in subgroups shows that metoprolol CR/XL was equally effective in middle aged and old patients, in men and women.
Sidorenko
B A
BA
Presidential Medical Center of Russia, Moscow, Russia.
Bugrimova
M A
MA
Iosava
I K
IK
Pataraia
S A
SA
Preobrazhenskiĭ
D V
DV
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D008790:Metoprolol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate / Q000639:trends; D016896:Treatment Outcome; D016277:Ventricular Function, Left
D000319:Adrenergic beta-Antagonists; D003692:Delayed-Action Preparations; D008790:Metoprolol